Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented Siolta Therapeutics, Inc., a biotech company developing live biotherapeutics that target the core drivers of disease, in its $12 million Series C Preferred Stock financing. The final closing of the round occurred on February 23, 2024.  The financing was led by Khosla Ventures and SymBiosis. The funds raised in this round will support the further clinical development of Siolta’s lead product, STMC-103H, a defined-consortia Live Biotherapeutic Product (LBP) focused on preventing the onset of atopic diseases in newborns. 

The team representing Siolta Therapeutics consisted of Daniel Zimmermann, Frances Mosley, Aric Jain and Amanda Rossetta.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel